DK3068428T3 - Annexin-ii-variant-sammensætninger og fremgangsmåder - Google Patents

Annexin-ii-variant-sammensætninger og fremgangsmåder Download PDF

Info

Publication number
DK3068428T3
DK3068428T3 DK14812331.8T DK14812331T DK3068428T3 DK 3068428 T3 DK3068428 T3 DK 3068428T3 DK 14812331 T DK14812331 T DK 14812331T DK 3068428 T3 DK3068428 T3 DK 3068428T3
Authority
DK
Denmark
Prior art keywords
annexin
methods
variant compositions
variant
compositions
Prior art date
Application number
DK14812331.8T
Other languages
English (en)
Inventor
John R Ohlfest
Michael R Olin
Original Assignee
Univ Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Minnesota filed Critical Univ Minnesota
Application granted granted Critical
Publication of DK3068428T3 publication Critical patent/DK3068428T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/15Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/461Cellular immunotherapy characterised by the cell type used
    • A61K39/4615Dendritic cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/462Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622Antigen presenting cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/46Cellular immunotherapy
    • A61K39/464Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643Vertebrate antigens
    • A61K39/4644Cancer antigens
    • A61K39/46449Melanoma antigens
    • A61K39/464492Glycoprotein 100 [Gp100]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
DK14812331.8T 2013-11-13 2014-11-13 Annexin-ii-variant-sammensætninger og fremgangsmåder DK3068428T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361903628P 2013-11-13 2013-11-13
PCT/US2014/065390 WO2015073632A1 (en) 2013-11-13 2014-11-13 Annexin ii variant compositions and methods

Publications (1)

Publication Number Publication Date
DK3068428T3 true DK3068428T3 (da) 2022-10-17

Family

ID=52101577

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14812331.8T DK3068428T3 (da) 2013-11-13 2014-11-13 Annexin-ii-variant-sammensætninger og fremgangsmåder

Country Status (9)

Country Link
US (1) US10206986B2 (da)
EP (1) EP3068428B1 (da)
AU (1) AU2014348645B2 (da)
CA (1) CA2930567C (da)
DK (1) DK3068428T3 (da)
ES (1) ES2928331T3 (da)
HU (1) HUE060293T2 (da)
PL (1) PL3068428T3 (da)
WO (1) WO2015073632A1 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016146143A1 (en) * 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
HRP20221372T1 (hr) * 2016-06-10 2023-01-06 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Domena jezgre aneksina i njihova upotreba u isporuci antigena i cijepljenju
KR20190057345A (ko) * 2016-09-21 2019-05-28 아말 테라퓨틱스 에스에이 암 치료를 위한, 세포 투과 펩타이드, 멀티 에피토프 및 tlr 펩타이드 작용제를 포함하는 융합체

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7262167B2 (en) 1995-11-06 2007-08-28 Exibona Ltd. Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites
US6645465B2 (en) 1999-08-06 2003-11-11 Michigan, University Of The Regents Annexin proteins and autoantibodies as serum markers for cancer
JP2004507482A (ja) * 2000-09-01 2004-03-11 フィラデルフィア・ヘルス・アンド・エデュケーション・コーポレーション 血管新生を阻害するための方法および組成物
DE10225144A1 (de) 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US7695725B2 (en) 2003-02-06 2010-04-13 Aduro Biotech Modified free-living microbes, vaccine compositions and methods of use thereof
EP2373338B1 (en) 2008-12-03 2017-02-15 The Johns Hopkins University Annexina2 as immunological target
KR101121198B1 (ko) * 2009-05-20 2012-03-23 (주)노바셀테크놀로지 태반에서 추출된 펩타이드 혼합물, 그의 제조 방법 및 용도
US9555074B2 (en) 2010-10-08 2017-01-31 Regents Of The University Of Minnesota Annexin II compositions

Also Published As

Publication number Publication date
CA2930567A1 (en) 2015-05-21
CA2930567C (en) 2023-09-26
PL3068428T3 (pl) 2023-03-13
HUE060293T2 (hu) 2023-02-28
US20160279212A1 (en) 2016-09-29
WO2015073632A1 (en) 2015-05-21
AU2014348645B2 (en) 2019-01-24
EP3068428B1 (en) 2022-08-17
EP3068428A1 (en) 2016-09-21
ES2928331T3 (es) 2022-11-17
AU2014348645A1 (en) 2016-06-02
US10206986B2 (en) 2019-02-19

Similar Documents

Publication Publication Date Title
DK3043784T3 (da) Arylethere og anvendelser deraf
DK3008168T3 (da) Sc-celler og sammensætninger og fremgangsmåde til dannelse deraf
BR112015028459A2 (pt) composições e comestíveis
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
DK3342773T3 (da) Syk-hæmmere
DK3613453T3 (da) Fordamper
DK3381917T3 (da) Imidazopyridinforbindelser og anvendelser deraf
DK3003039T3 (da) Methyl/fluor-pyridinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser og fluor-pyrimidinyl-metoxy-substituerede pyridinon-pyridinyl-forbindelser
DK3063144T3 (da) Antiparasitære og pesticid-isoxazolinforbindelser
DK3077467T3 (da) Sikkativsammensætning og anvendelse deraf
DK2962100T3 (da) Tuberkulosebiomarkører og anvendelser deraf
DK3065771T3 (da) Fremgangsmåder og sammensætninger til vedvarende immunterapi
DK2986722T3 (da) Manipulerede phenylalaninammoniak-lyasepolypeptider
DK3030549T3 (da) Pyridazinonforbindelser og anvendelser deraf
DK3060200T3 (da) Tyrosinderivater og sammensætninger dermed
DK3077047T3 (da) Aramcholsalte
DK3029038T3 (da) Tetrazolinonforbindelse og anvendelse deraf
DK3027750T3 (da) Biokatalytisk sammensætning
DK3060460T3 (da) Saddel
DK3027598T3 (da) Oxoquinazolinyl-butanamidderivater
DK3058936T3 (da) Peptidsammensætning og anvendelser deraf
DK2956698T5 (da) Bindestrimler
DK3052081T3 (da) Pastil
DK2946640T3 (da) Langmuir-probe
DK2849798T3 (da) Oligonukleotid-chelatkompleks-polypeptidsammensætninger og fremgangsmåder